UNSPSC 51343511: Tenofovir disoproxil

This classification denotes a reverse transcriptase inhibitor and purine antagonist C19H30N5O10P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4YU4LON7I, chemically known as 2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(((1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-, 1,9-bis(1-methylethyl) ester, 5-oxide, but more generally known as tenofovir disoproxil, which bears US NIH Compound Identifier 5481350.

UNSPSC 51343511 Tenofovir disoproxil is a Commodity code for a specific antiretroviral pharmaceutical product, but recent state and local procurement activity under this code does not reflect actual purchasing of tenofovir disoproxil. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, tagged to this code but supplying Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets instead. Seminole County, Florida posted an IFB on June 30, 2026, for Naloxone and Safe Drug Deactivation Systems, which is similarly misaligned with the code's nominal scope. The code shows little relevant recent activity; the two tagged opportunities represent unrelated pharmaceutical products and public health supplies.

When state and local procurement offices do solicit under broad pharmaceutical codes, they typically acquire through cooperative purchasing agreements and piggyback arrangements rather than standalone RFPs, as the Illinois award illustrates. The geographic activity recorded here spans Florida and Illinois, but the mismatch between code assignment and actual scope limits the utility of this code for vendors specializing in tenofovir disoproxil or related antiretroviral products. Firms pursuing state and local tenofovir opportunities should monitor health department and Medicaid-agency solicitations directly rather than rely on this code classification.